###begin article-title 0
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease
###end article-title 0
###begin p 1
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 1009 1017 <span type="species:ncbi:9606">patients</span>
It has previously been shown that immune complexes (IC) of a given biomarker with class M immunoglobulins (IgM) provide better performances compared to the unbound biomarker in a number of cancer entities. In the present work, we investigated IC of IgM-Abeta as a potential biomarker for Alzheimer's disease (AD). Abeta-IgM concentration has been measured in 75 plasma samples from patients with AD, individuals with mild cognitive impairment (MCI), and healthy age- and sex-matched controls (HC). To characterize the fractions associated with Abeta, pooled plasma samples were subjected to gel-filtration analysis. Size-separated fractions were analyzed for the presence of Abeta using a sandwich ELISA assay. A strong reactivity was observed in the high molecular weight IgM (>500 kDa) and 150 kDa (IgG) fractions indicating that blood Abeta is strongly associated with antibodies. Using an ELISA assay detecting Abeta-IgM complexes, we observed that high levels of Abeta-IgMs were detectable in HC and MCI patients; however, there was no significant difference to the AD group.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">1999</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">2001</xref>
###xml 511 515 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2002</xref>
###xml 667 671 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2004</xref>
###xml 687 691 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">1999</xref>
###xml 708 712 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2004</xref>
###xml 815 819 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2001</xref>
###xml 865 869 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2005</xref>
###xml 1100 1104 1088 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2007</xref>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 792 800 <span type="species:ncbi:9606">patients</span>
The earliest pathological events leading to Alzheimer's disease (AD) are estimated to occur 10-20 years before the appearance of the first cognitive changes in affected patients (Price and Morris 1999; Yamaguchi et al. 2001). Therefore, identification of biomarkers predictive for AD might allow screening for individuals who may benefit from preventive therapies before the development of cognitive impairment. The Abeta42 peptide is supposed to have a central role in the pathogenesis of AD (Hardy and Selkoe 2002), and its measurement in the cerebrospinal fluid (CSF) became nowadays a routine diagnostic procedure with 75-95% sensitivity and specificity (Blennow 2004; Jensen et al. 1999; Lewczuk et al. 2004). Unfortunately, CSF and blood levels of Abeta do not correlate, neither in AD patients (Mehta et al. 2001) nor in healthy controls (Mehta and Pirttila 2005). On the other side, it has been also shown that there is a correlation between CSF and plasma levels of Abeta40 and Abeta42 in healthy individuals, whereas no such correlation could be seen for AD or MCI cases (Giedraitis et al. 2007).
###end p 4
###begin p 5
###xml 177 181 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2008</xref>
###xml 216 220 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2003</xref>
###xml 244 248 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2000</xref>
###xml 304 308 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">1999</xref>
###xml 626 630 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2008</xref>
###xml 1065 1069 1029 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2008</xref>
###xml 1392 1396 1350 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2000</xref>
###xml 1412 1416 1370 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">1994</xref>
###xml 1722 1726 1673 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1996</xref>
###xml 1739 1743 1690 1694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2000</xref>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
###xml 1398 1404 <span type="species:ncbi:8164">Suzuki</span>
Studies on plasma Abeta levels have shown contradictory results, ranging from increased Abeta40 and decreased Abeta42 in AD patients compared to healthy controls (Xu and Gaskin 2008), no differences (Fukumoto et al. 2003; Vanderstichele et al. 2000) or increased Abeta42 in AD patients (Matsubara et al. 1999). The different findings in these studies may be due to differences in study designs, including variations in age and disease severity of included subjects. A longitudinal study showed that plasma Abeta40 and Abeta42 levels measured at age 70 years were not significantly associated with incident AD (Sundelof et al. 2008). All of the studies though, have shown substantial overlap in plasma Abeta40 and Abeta42 levels between patients and controls, thus limiting the diagnostic value of plasma Abeta assessment. Although the significance of Abeta for diagnosing Alzheimer's disease is controversial, high plasma concentrations of Abeta40 and low plasma concentrations of Abeta42 indicate an increased risk of dementia (reviewed in Kawarabayashi and Shoji 2008). Nonetheless, analysis of plasma instead of CSF would be highly desirable because of its better accessibility and less invasive sampling procedure. Plasma Abeta levels are commonly quantified with enzyme-linked immunoabsorbent assays (ELISA) using antibodies against a variety of Abeta epitopes (for example Mehta et al. 2000; Suzuki et al. 1994). Quantification of Abeta in blood is technically difficult and limited by the fact that most of it is bound to blood components, including lipids serum albumin, alpha2-macroglobulin, immunoglobulins, apolipoprotein J, transthyritin, apoferritin, as well as complement components C1q and C3 (Biere et al. 1996; Kuo et al. 2000).
###end p 5
###begin p 6
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2004</xref>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2003</xref>
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">1996</xref>
###xml 429 433 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2001</xref>
###xml 555 559 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2001</xref>
###xml 567 571 564 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">1997</xref>
###xml 590 594 587 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2003</xref>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
Besides the detection of biochemical AD markers, autoimmune responses to molecules specific to AD pathology have become a current research focus (Gruden et al. 2004; Nath et al. 2003). There seems to be a reduction in the magnitude of lymphocyte stimulation by APP in AD patients (Trieb et al. 1996), and naturally occurring anti-Abeta antibodies seem to be present in sera and CSF of AD patients and healthy controls (Du et al. 2001). However, whether autoimmunity plays a direct role in the pathogenesis of AD is still open to debate (McGeer and McGeer 2001; Singh 1997; Tarkowski et al. 2003).
###end p 6
###begin p 7
###xml 243 247 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 271 275 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2005</xref>
In the present study, the level of circulating immune complexes (ICs) between Abeta and class M immunoglobulins (IgM) has been investigated, because ICs have been shown to be relevant biomarkers for different types of cancers (Beneduce et al. 2005, 2006; Castaldi et al. 2005), showing an improved diagnostic power compared to the free biomarker protein.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples
###end title 9
###begin p 10
###xml 375 379 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2000</xref>
###xml 414 418 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">1984</xref>
###xml 480 484 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">2004</xref>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
Plasma samples (stored at -70degreesC) from 30 out-patients with mild to moderate AD, 15 patients with mild cognitive impairment (MCI) and 30 healthy controls (HC) were analyzed. The patients were recruited at the Memory Clinic at the Department of Geriatrics, Uppsala University Hospital. All AD patients were diagnosed according to DSM IV (American Psychiatric Association 2000) and NINCDS-ADRDA (McKhann et al. 1984). The MCI patients met the Petersen criteria (Winblad et al. 2004) for MCI.
###end p 10
###begin title 11
Gel filtration
###end title 11
###begin p 12
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Plasma samples from five AD patients and five healthy controls showing high reactivity to Abeta-IgM immune complexes in a preliminary assay were grouped and analyzed by gel-filtration HPLC. 500 microl of pooled samples were analyzed using a gel-filtration column Superdex 200 10/300 GL (GE Healthcare, Freiburg, Germany) on an ACTA Basic system (GE Healthcare, Freiburg, Germany). The elution was carried out in PBS at a flow rate of 1 ml per minute, and sample absorbance was monitored at 280 nm. Fractions were collected every 30 s, immunoreactivity was tested by ELISA and the fractions corresponding to the highest immunoreactivity were pooled and used as reference standard. Before running the samples, a calibration run was carried out according to the manufacturer's instructions.
###end p 12
###begin title 13
ELISA assay to detect Abeta
###end title 13
###begin p 14
###xml 140 145 <span type="species:ncbi:10090">mouse</span>
###xml 151 156 <span type="species:ncbi:9606">human</span>
###xml 573 579 <span type="species:ncbi:9986">rabbit</span>
###xml 773 777 <span type="species:ncbi:9925">goat</span>
###xml 783 789 <span type="species:ncbi:9986">rabbit</span>
The Abeta level in gel-filtration fractions was determined as follows: 96-well ELISA plates were coated with 50 mul per well of 1 mug/ml of mouse anti-human Abeta antibody directed against residues 17-24 (4G8, Signet Laboratories, Dedham, MA, USA) in PBS at 4degreesC overnight and then blocked for 2 h with 3% BSA in PBS at 37degreesC. After blocking, 50 mul of gel-filtration fractions in PBS containing 1% BSA and 0.05% Tween 20 (PBS-B-T) were incubated for 1.5 h at 37degreesC. The wells were then washed with PBS containing 0.05% Tween 20 and incubated with 50 mul of rabbit polyclonal anti-Abeta 692 (generous gift from Gerd Multhaup, Free University of Berlin) at a 1:1,000 dilution in PBS-B-T for 1.5 h at 37degreesC. Abeta was revealed using peroxidase-conjugated goat anti-rabbit IgG (Dako, Glostrup, Denmark) in a 1:1,000 dilution in PBS-B-T and developed with TMB (Pierce manufacturing, Appleton, IL, USA) and hydrogen peroxide as substrate. The results of Abeta determination in the gel-filtration fractions were reported in optical density.
###end p 14
###begin title 15
ELISA assay to detect Abeta-IgM immune complexes
###end title 15
###begin p 16
###xml 385 390 <span type="species:ncbi:9606">human</span>
96-well ELISA plates were coated with 50 muL per well of 1 mug/mL 4G8 antibody (Signet Laboratories, Dedham, MA, USA) in PBS at 4degreesC overnight and then blocked for 2 h with 3% BSA in PBS. After blocking, 50 mul of serially diluted reference standard or samples in PBS-B-T were incubated for 1.5 h at 37degreesC. The Abeta-IgM complex was revealed using peroxidase-conjugated anti-human IgM (Sigma-Aldrich, Munich, Germany) at a dilution of 1:3,000 in PBS-B-T and developed with TMB and hydrogen peroxide as the substrate. Abeta-IgM IC levels in the plasma were expressed in arbitrary units/ml (AU/ml) by using gel-filtration-purified Abeta-IgM reference standards to design a calibration curve, where the undiluted standard was assigned 1,000 AU/ml; concentration was determined by interpolation of samples absorbance on the calibration curve. The linear range of the assay was between 3.9 and 62.5 AU/ml. The samples with values above 62.5 AU/ml were further diluted and re-measured. The assay was standardized and its analytical performance evaluated: inter- and intra-assay coefficient of variation (CV) was less than 10%. Abeta-IgM cut-off was selected as the best combination of specificity and sensitivity according to the receiver-operating characteristic (ROC) curve.
###end p 16
###begin title 17
Western blot
###end title 17
###begin p 18
###xml 403 407 <span type="species:ncbi:9925">goat</span>
###xml 413 418 <span type="species:ncbi:9606">human</span>
Gel-filtration fractions corresponding to 280 nm absorbance peaks were separated on a 4-12% variogel (Anamed, Gross-Bieberau, Germany) and then transferred to a nitrocellulose membrane. The membrane was heated in PBS in a microwave for 5 min and then blocked in 10% non-fat dry milk in TBS containing 0.05% Tween (TBS-T) for 1 h at room temperature. Blots were then incubated with peroxidase-conjugated goat anti-human IgM (Sigma-Aldrich) at 1:1,000 in TBS-T for 2 h or, alternatively, with a primary antibody directed against Abeta residues 4-10 (W0-2, The Genetics Company, Switzerland) overnight at 4degreesC and secondary peroxidase-conjugated antibodies for 2 h at room temperature. Protein bands were revealed using chemiluminescence solution and peroxide hydrogen as substrates on a Curix60 developing machine (Agfa-Gevaert N.V., Mortsel, Belgium).
###end p 18
###begin title 19
Data analysis
###end title 19
###begin p 20
###xml 151 152 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 399 406 <span type="species:ncbi:9606">patient</span>
All biomarker values were expressed as mean values +/- standard deviation. Differences between the groups were determined by ANOVA followed by Student t tests. The diagnostic powers were determined by ROC curve analysis. Chi-square test on independence was used to analyze, if the gender distribution was significantly different between the three groups and if there is a difference between the two patient groups in relation to the number of family members with dementia. All analyses were performed using GraphPad Prism (GraphPad software, Inc., La Jolla, CA, USA and SPSS 16 for Windows). Significance level was alpha = 0.05. All tests were two-tailed.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 129 131 129 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 260 262 260 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 369 371 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 486 488 484 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 494 495 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 631 633 627 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 639 640 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 656 657 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 659 666 655 662 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 666 704 662 700 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">Demographic data of the studied groups</p>
###xml 666 704 662 700 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">Demographic data of the studied groups</p></caption>
###xml 704 704 700 700 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 704 706 700 702 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">AD</th>
###xml 706 709 702 705 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">MCI</th>
###xml 709 711 705 707 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">HC</th>
###xml 714 715 710 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 711 715 707 711 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Chi<sup>2</sup></th>
###xml 715 717 711 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 715 717 711 713 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>df</italic></th>
###xml 717 718 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 717 718 713 714 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 704 718 700 714 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left" colspan="2">AD</th><th align="left" colspan="2">MCI</th><th align="left" colspan="2">HC</th><th align="left">Chi<sup>2</sup></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr>
###xml 704 718 700 714 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left" colspan="2">AD</th><th align="left" colspan="2">MCI</th><th align="left" colspan="2">HC</th><th align="left">Chi<sup>2</sup></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead>
###xml 718 739 714 735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gender (male, female)</td>
###xml 739 751 735 747 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">M: 12, F: 18</td>
###xml 751 761 747 757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">M: 8, F: 7</td>
###xml 761 772 757 768 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">M:11, F: 19</td>
###xml 772 775 768 771 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.2</td>
###xml 775 776 771 772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 776 780 772 776 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.55</td>
###xml 718 780 714 776 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Gender (male, female)</td><td align="left" colspan="2">M: 12, F: 18</td><td align="left" colspan="2">M: 8, F: 7</td><td align="left" colspan="2">M:11, F: 19</td><td char="." align="char">1.2</td><td align="left">2</td><td char="." align="char">0.55</td></tr>
###xml 780 798 776 794 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dementia in family</td>
###xml 798 813 794 809 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Yes: 16, no: 12</td>
###xml 813 826 809 822 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Yes: 6, no: 8</td>
###xml 826 826 822 822 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2"/>
###xml 826 829 822 825 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.8</td>
###xml 829 830 825 826 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 830 834 826 830 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.38</td>
###xml 780 834 776 830 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Dementia in family</td><td align="left" colspan="2">Yes: 16, no: 12</td><td align="left" colspan="2">Yes: 6, no: 8</td><td align="left" colspan="2"/><td char="." align="char">0.8</td><td align="left">1</td><td char="." align="char">0.38</td></tr>
###xml 718 834 714 830 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Gender (male, female)</td><td align="left" colspan="2">M: 12, F: 18</td><td align="left" colspan="2">M: 8, F: 7</td><td align="left" colspan="2">M:11, F: 19</td><td char="." align="char">1.2</td><td align="left">2</td><td char="." align="char">0.55</td></tr><tr><td align="left">Dementia in family</td><td align="left" colspan="2">Yes: 16, no: 12</td><td align="left" colspan="2">Yes: 6, no: 8</td><td align="left" colspan="2"/><td char="." align="char">0.8</td><td align="left">1</td><td char="." align="char">0.38</td></tr></tbody>
###xml 704 834 700 830 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">AD</th><th align="left" colspan="2">MCI</th><th align="left" colspan="2">HC</th><th align="left">Chi<sup>2</sup></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Gender (male, female)</td><td align="left" colspan="2">M: 12, F: 18</td><td align="left" colspan="2">M: 8, F: 7</td><td align="left" colspan="2">M:11, F: 19</td><td char="." align="char">1.2</td><td align="left">2</td><td char="." align="char">0.55</td></tr><tr><td align="left">Dementia in family</td><td align="left" colspan="2">Yes: 16, no: 12</td><td align="left" colspan="2">Yes: 6, no: 8</td><td align="left" colspan="2"/><td char="." align="char">0.8</td><td align="left">1</td><td char="." align="char">0.38</td></tr></tbody></table>
###xml 834 834 830 830 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 834 835 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 834 835 830 831 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic></th>
###xml 835 843 831 837 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">m&#160;&#177;&#160;SD</th>
###xml 843 844 837 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 843 844 837 838 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic></th>
###xml 844 852 838 844 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">m&#160;&#177;&#160;SD</th>
###xml 852 853 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 852 853 844 845 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>n</italic></th>
###xml 853 861 845 851 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">m&#160;&#177;&#160;SD</th>
###xml 861 862 851 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 861 862 851 852 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>F</italic></th>
###xml 862 864 852 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 862 864 852 854 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>df</italic></th>
###xml 864 865 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 864 865 854 855 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 834 865 830 855 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>F</italic></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr>
###xml 834 865 830 855 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>F</italic></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead>
###xml 865 876 855 866 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (years)</td>
###xml 876 878 866 868 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30</td>
###xml 878 890 868 878 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">72.3&#160;&#177;&#160;6.7</td>
###xml 890 892 878 880 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">15</td>
###xml 892 904 880 890 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">73.7&#160;&#177;&#160;4.3</td>
###xml 904 906 890 892 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30</td>
###xml 906 918 892 902 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">72.5&#160;&#177;&#160;5.2</td>
###xml 918 921 902 905 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.3</td>
###xml 921 926 905 910 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2, 72</td>
###xml 926 930 910 914 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.74</td>
###xml 865 930 855 914 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age (years)</td><td align="left">30</td><td char="&#177;" align="char">72.3&#160;&#177;&#160;6.7</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">73.7&#160;&#177;&#160;4.3</td><td align="left">30</td><td align="left">72.5&#160;&#177;&#160;5.2</td><td char="." align="char">0.3</td><td align="left">2, 72</td><td char="." align="char">0.74</td></tr>
###xml 930 950 914 934 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age at onset (years)</td>
###xml 950 952 934 936 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30</td>
###xml 952 964 936 946 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">67.9&#160;&#177;&#160;7.9</td>
###xml 964 966 946 948 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">14</td>
###xml 966 978 948 958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">71.4&#160;&#177;&#160;4.9</td>
###xml 978 978 958 958 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 978 978 958 958 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 978 981 958 961 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.3</td>
###xml 981 986 961 966 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1, 42</td>
###xml 986 990 966 970 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.13</td>
###xml 930 990 914 970 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age at onset (years)</td><td align="left">30</td><td char="&#177;" align="char">67.9&#160;&#177;&#160;7.9</td><td char="&#177;" align="char">14</td><td char="&#177;" align="char">71.4&#160;&#177;&#160;4.9</td><td align="left"/><td align="left"/><td char="." align="char">2.3</td><td align="left">1, 42</td><td char="." align="char">0.13</td></tr>
###xml 990 1009 970 989 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MMSE (at screening)</td>
###xml 1009 1011 989 991 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">27</td>
###xml 1011 1023 991 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">17.3&#160;&#177;&#160;6.1</td>
###xml 1023 1025 1001 1003 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">15</td>
###xml 1025 1037 1003 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">27.9&#160;&#177;&#160;1.3</td>
###xml 1037 1037 1013 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1037 1037 1013 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1037 1041 1013 1017 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">44.3</td>
###xml 1041 1046 1017 1022 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1, 40</td>
###xml 1046 1053 1022 1029 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0005</td>
###xml 990 1053 970 1029 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">MMSE (at screening)</td><td align="left">27</td><td char="&#177;" align="char">17.3&#160;&#177;&#160;6.1</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">27.9&#160;&#177;&#160;1.3</td><td align="left"/><td align="left"/><td char="." align="char">44.3</td><td align="left">1, 40</td><td char="." align="char">&lt;0.0005</td></tr>
###xml 865 1053 855 1029 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Age (years)</td><td align="left">30</td><td char="&#177;" align="char">72.3&#160;&#177;&#160;6.7</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">73.7&#160;&#177;&#160;4.3</td><td align="left">30</td><td align="left">72.5&#160;&#177;&#160;5.2</td><td char="." align="char">0.3</td><td align="left">2, 72</td><td char="." align="char">0.74</td></tr><tr><td align="left">Age at onset (years)</td><td align="left">30</td><td char="&#177;" align="char">67.9&#160;&#177;&#160;7.9</td><td char="&#177;" align="char">14</td><td char="&#177;" align="char">71.4&#160;&#177;&#160;4.9</td><td align="left"/><td align="left"/><td char="." align="char">2.3</td><td align="left">1, 42</td><td char="." align="char">0.13</td></tr><tr><td align="left">MMSE (at screening)</td><td align="left">27</td><td char="&#177;" align="char">17.3&#160;&#177;&#160;6.1</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">27.9&#160;&#177;&#160;1.3</td><td align="left"/><td align="left"/><td char="." align="char">44.3</td><td align="left">1, 40</td><td char="." align="char">&lt;0.0005</td></tr></tbody>
###xml 834 1053 830 1029 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>F</italic></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">30</td><td char="&#177;" align="char">72.3&#160;&#177;&#160;6.7</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">73.7&#160;&#177;&#160;4.3</td><td align="left">30</td><td align="left">72.5&#160;&#177;&#160;5.2</td><td char="." align="char">0.3</td><td align="left">2, 72</td><td char="." align="char">0.74</td></tr><tr><td align="left">Age at onset (years)</td><td align="left">30</td><td char="&#177;" align="char">67.9&#160;&#177;&#160;7.9</td><td char="&#177;" align="char">14</td><td char="&#177;" align="char">71.4&#160;&#177;&#160;4.9</td><td align="left"/><td align="left"/><td char="." align="char">2.3</td><td align="left">1, 42</td><td char="." align="char">0.13</td></tr><tr><td align="left">MMSE (at screening)</td><td align="left">27</td><td char="&#177;" align="char">17.3&#160;&#177;&#160;6.1</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">27.9&#160;&#177;&#160;1.3</td><td align="left"/><td align="left"/><td char="." align="char">44.3</td><td align="left">1, 40</td><td char="." align="char">&lt;0.0005</td></tr></tbody></table>
###xml 1053 1055 1029 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 1077 1080 1053 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCI</italic>
###xml 1118 1120 1094 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HC</italic>
###xml 1139 1140 1115 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 1147 1149 1123 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SD</italic>
###xml 1170 1173 1146 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chi</italic>
###xml 1173 1174 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1173 1174 1149 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sup>
###xml 1197 1198 1173 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1212 1214 1188 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 1235 1236 1211 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1250 1251 1226 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 1258 1259 1234 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1053 1266 1029 1242 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24"><italic>AD</italic> Alzheimer&#8217;s disease, <italic>MCI</italic> mild cognitive impaired individuals, <italic>HC</italic> healthy controls, <italic>m</italic> mean, <italic>SD</italic> standard deviation, <italic>Chi</italic><sup><italic>2</italic></sup> Chi-square statistic, <italic>F</italic> F-statistic, <italic>df</italic> degrees of freedom, <italic>P</italic> probability, <italic>M</italic> male, <italic>F</italic> female</p>
###xml 1053 1266 1029 1242 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24"><italic>AD</italic> Alzheimer&#8217;s disease, <italic>MCI</italic> mild cognitive impaired individuals, <italic>HC</italic> healthy controls, <italic>m</italic> mean, <italic>SD</italic> standard deviation, <italic>Chi</italic><sup><italic>2</italic></sup> Chi-square statistic, <italic>F</italic> F-statistic, <italic>df</italic> degrees of freedom, <italic>P</italic> probability, <italic>M</italic> male, <italic>F</italic> female</p></table-wrap-foot>
###xml 659 1266 655 1242 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="23">Demographic data of the studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">AD</th><th align="left" colspan="2">MCI</th><th align="left" colspan="2">HC</th><th align="left">Chi<sup>2</sup></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Gender (male, female)</td><td align="left" colspan="2">M: 12, F: 18</td><td align="left" colspan="2">M: 8, F: 7</td><td align="left" colspan="2">M:11, F: 19</td><td char="." align="char">1.2</td><td align="left">2</td><td char="." align="char">0.55</td></tr><tr><td align="left">Dementia in family</td><td align="left" colspan="2">Yes: 16, no: 12</td><td align="left" colspan="2">Yes: 6, no: 8</td><td align="left" colspan="2"/><td char="." align="char">0.8</td><td align="left">1</td><td char="." align="char">0.38</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>n</italic></th><th align="left">m&#160;&#177;&#160;SD</th><th align="left"><italic>F</italic></th><th align="left"><italic>df</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">30</td><td char="&#177;" align="char">72.3&#160;&#177;&#160;6.7</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">73.7&#160;&#177;&#160;4.3</td><td align="left">30</td><td align="left">72.5&#160;&#177;&#160;5.2</td><td char="." align="char">0.3</td><td align="left">2, 72</td><td char="." align="char">0.74</td></tr><tr><td align="left">Age at onset (years)</td><td align="left">30</td><td char="&#177;" align="char">67.9&#160;&#177;&#160;7.9</td><td char="&#177;" align="char">14</td><td char="&#177;" align="char">71.4&#160;&#177;&#160;4.9</td><td align="left"/><td align="left"/><td char="." align="char">2.3</td><td align="left">1, 42</td><td char="." align="char">0.13</td></tr><tr><td align="left">MMSE (at screening)</td><td align="left">27</td><td char="&#177;" align="char">17.3&#160;&#177;&#160;6.1</td><td char="&#177;" align="char">15</td><td char="&#177;" align="char">27.9&#160;&#177;&#160;1.3</td><td align="left"/><td align="left"/><td char="." align="char">44.3</td><td align="left">1, 40</td><td char="." align="char">&lt;0.0005</td></tr></tbody></table><table-wrap-foot><p textid="24"><italic>AD</italic> Alzheimer&#8217;s disease, <italic>MCI</italic> mild cognitive impaired individuals, <italic>HC</italic> healthy controls, <italic>m</italic> mean, <italic>SD</italic> standard deviation, <italic>Chi</italic><sup><italic>2</italic></sup> Chi-square statistic, <italic>F</italic> F-statistic, <italic>df</italic> degrees of freedom, <italic>P</italic> probability, <italic>M</italic> male, <italic>F</italic> female</p></table-wrap-foot></table-wrap>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 88 90 <span type="species:ncbi:9606">AD</span>
###xml 152 160 <span type="species:ncbi:9606">Patients</span>
###xml 238 240 <span type="species:ncbi:9606">AD</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 346 348 <span type="species:ncbi:9606">AD</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
There were no significant age differences between the three groups [Alzheimer patients (AD), MCI and healthy controls] (F = 0.3, df = 2, 72; P = 0.74). Patients with MCI diagnosis were not significantly older at onset of the disease than AD patients (F = 2.3, df = 1, 42; P = 0.13). As expected, the mean MMSE score was higher in MCI compared to AD patients (F = 44.3, df = 1, 40; P < 0.0005). Gender distribution was not significantly different between the three groups (Chi(2) = 1.2, df = 2; P = 0.55) and the proportion of family members with dementia did not differ significantly between the two patients groups (Chi(2) = 0.8, df = 1; P = 0.38) (Table 1).Table 1Demographic data of the studied groupsADMCIHCChi2dfPGender (male, female)M: 12, F: 18M: 8, F: 7M:11, F: 191.220.55Dementia in familyYes: 16, no: 12Yes: 6, no: 80.810.38nm +/- SDnm +/- SDnm +/- SDFdfPAge (years)3072.3 +/- 6.71573.7 +/- 4.33072.5 +/- 5.20.32, 720.74Age at onset (years)3067.9 +/- 7.91471.4 +/- 4.92.31, 420.13MMSE (at screening)2717.3 +/- 6.11527.9 +/- 1.344.31, 40<0.0005AD Alzheimer's disease, MCI mild cognitive impaired individuals, HC healthy controls, m mean, SD standard deviation, Chi2 Chi-square statistic, F F-statistic, df degrees of freedom, P probability, M male, F female
###end p 22
###begin p 23
Demographic data of the studied groups
###end p 23
###begin p 24
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 24 27 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCI</italic>
###xml 65 67 65 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HC</italic>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 94 96 94 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SD</italic>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chi</italic>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sup>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 159 161 159 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 0 2 <span type="species:ncbi:9606">AD</span>
AD Alzheimer's disease, MCI mild cognitive impaired individuals, HC healthy controls, m mean, SD standard deviation, Chi2 Chi-square statistic, F F-statistic, df degrees of freedom, P probability, M male, F female
###end p 24
###begin p 25
###xml 379 380 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 556 557 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 822 826 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2000</xref>
###xml 975 976 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 979 985 955 961 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 985 986 961 962 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1202 1211 1178 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray line</italic>
###xml 1442 1450 1415 1423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">diamonds</italic>
###xml 1597 1598 1564 1565 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1647 1650 1611 1614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgM</italic>
###xml 985 1718 961 1679 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26"><bold>a</bold> Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280&#160;nm (<italic>gray line</italic>). The characteristic peaks were as follows: empty volume with a MW&#160;&gt;&#160;500&#160;kDa (IgMs), IgGs with a MW of ~150&#160;kDa, and the albumin peak at ~66&#160;kDa. A direct ELISA performed on each fraction to measure the quantity of generic A&#946; (<italic>diamonds</italic>) shows that most of A&#946; elutes in the empty volume and IgG fractions suggesting that A&#946; in the blood is strongly associated with antibodies. <bold>b</bold> Western blot against A&#946; in the empty volume (<italic>IgM</italic>) fraction and IgM showing the presence of A&#946; in the IgM fraction</p>
###xml 985 1718 961 1679 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26"><bold>a</bold> Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280&#160;nm (<italic>gray line</italic>). The characteristic peaks were as follows: empty volume with a MW&#160;&gt;&#160;500&#160;kDa (IgMs), IgGs with a MW of ~150&#160;kDa, and the albumin peak at ~66&#160;kDa. A direct ELISA performed on each fraction to measure the quantity of generic A&#946; (<italic>diamonds</italic>) shows that most of A&#946; elutes in the empty volume and IgG fractions suggesting that A&#946; in the blood is strongly associated with antibodies. <bold>b</bold> Western blot against A&#946; in the empty volume (<italic>IgM</italic>) fraction and IgM showing the presence of A&#946; in the IgM fraction</p></caption>
###xml 1718 1718 1679 1679 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_224_Fig1_HTML" id="MO1"/>
###xml 979 1718 955 1679 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="26"><bold>a</bold> Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280&#160;nm (<italic>gray line</italic>). The characteristic peaks were as follows: empty volume with a MW&#160;&gt;&#160;500&#160;kDa (IgMs), IgGs with a MW of ~150&#160;kDa, and the albumin peak at ~66&#160;kDa. A direct ELISA performed on each fraction to measure the quantity of generic A&#946; (<italic>diamonds</italic>) shows that most of A&#946; elutes in the empty volume and IgG fractions suggesting that A&#946; in the blood is strongly associated with antibodies. <bold>b</bold> Western blot against A&#946; in the empty volume (<italic>IgM</italic>) fraction and IgM showing the presence of A&#946; in the IgM fraction</p></caption><graphic position="anchor" xlink:href="702_2009_224_Fig1_HTML" id="MO1"/></fig>
###xml 1718 1724 1679 1685 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1724 1725 1685 1686 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2020 2021 1978 1979 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2090 2091 2048 2049 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2103 2111 2058 2066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">diamonds</italic>
###xml 2221 2231 2176 2186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid line</italic>
###xml 1724 2232 1685 2187 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27"><bold>a</bold> Sandwich ELISA. 96-well titer plates are coated with anti-A&#946; (4G8). After incubation with plasma samples, the wells are washed and incubated with an anti-IgM heavy chain antibody conjugated with HRP. Signal of bound molecules is therefore only produced by complexes of both IgM and antigen. <bold>b</bold> Calibration curve obtained by serial dilutions of the IgM fraction. <bold>c</bold> A&#946;-IgM (<italic>diamonds</italic>) immune complexes in the fractions derived from gel-filtration HPLC compared to total protein concentration (<italic>solid line</italic>)</p>
###xml 1724 2232 1685 2187 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27"><bold>a</bold> Sandwich ELISA. 96-well titer plates are coated with anti-A&#946; (4G8). After incubation with plasma samples, the wells are washed and incubated with an anti-IgM heavy chain antibody conjugated with HRP. Signal of bound molecules is therefore only produced by complexes of both IgM and antigen. <bold>b</bold> Calibration curve obtained by serial dilutions of the IgM fraction. <bold>c</bold> A&#946;-IgM (<italic>diamonds</italic>) immune complexes in the fractions derived from gel-filtration HPLC compared to total protein concentration (<italic>solid line</italic>)</p></caption>
###xml 2232 2232 2187 2187 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_224_Fig2_HTML" id="MO2"/>
###xml 1718 2232 1679 2187 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="27"><bold>a</bold> Sandwich ELISA. 96-well titer plates are coated with anti-A&#946; (4G8). After incubation with plasma samples, the wells are washed and incubated with an anti-IgM heavy chain antibody conjugated with HRP. Signal of bound molecules is therefore only produced by complexes of both IgM and antigen. <bold>b</bold> Calibration curve obtained by serial dilutions of the IgM fraction. <bold>c</bold> A&#946;-IgM (<italic>diamonds</italic>) immune complexes in the fractions derived from gel-filtration HPLC compared to total protein concentration (<italic>solid line</italic>)</p></caption><graphic position="anchor" xlink:href="702_2009_224_Fig2_HTML" id="MO2"/></fig>
In order to identify circulating Abeta-IgM complexes, plasma samples from ten individuals were pooled and analyzed by gel filtration. Fractions collected from the column were tested for the presence of generic Abeta and Abeta-IgM complexes using ELISA assays. A strong immunoreactivity against Abeta was observed in the fraction eluting at high molecular weight (>500 kDa) (Fig. 1a). In the same fraction high reactivity for ICs of Abeta with IgM was also found, thus providing the first evidence of the occurrence of circulating Abeta-IgM complexes (Fig. 2c). Reactivity for generic Abeta was also found in the fractions eluting at 150 kDa (IgG fraction) and at low molecular weight (not shown). Reactivity against the monomeric form of Abeta has been found in all fractions, confirming previous observations (Kuo et al. 2000). The fractions contained components migrating at the expected molecular weight for reduced IgM that were stained by antihuman IgM antibodies (Fig. 1b).Fig. 1a Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280 nm (gray line). The characteristic peaks were as follows: empty volume with a MW > 500 kDa (IgMs), IgGs with a MW of ~150 kDa, and the albumin peak at ~66 kDa. A direct ELISA performed on each fraction to measure the quantity of generic Abeta (diamonds) shows that most of Abeta elutes in the empty volume and IgG fractions suggesting that Abeta in the blood is strongly associated with antibodies. b Western blot against Abeta in the empty volume (IgM) fraction and IgM showing the presence of Abeta in the IgM fractionFig. 2a Sandwich ELISA. 96-well titer plates are coated with anti-Abeta (4G8). After incubation with plasma samples, the wells are washed and incubated with an anti-IgM heavy chain antibody conjugated with HRP. Signal of bound molecules is therefore only produced by complexes of both IgM and antigen. b Calibration curve obtained by serial dilutions of the IgM fraction. c Abeta-IgM (diamonds) immune complexes in the fractions derived from gel-filtration HPLC compared to total protein concentration (solid line)
###end p 25
###begin p 26
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 217 226 217 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray line</italic>
###xml 457 465 454 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">diamonds</italic>
###xml 612 613 603 604 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 662 665 650 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IgM</italic>
a Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280 nm (gray line). The characteristic peaks were as follows: empty volume with a MW > 500 kDa (IgMs), IgGs with a MW of ~150 kDa, and the albumin peak at ~66 kDa. A direct ELISA performed on each fraction to measure the quantity of generic Abeta (diamonds) shows that most of Abeta elutes in the empty volume and IgG fractions suggesting that Abeta in the blood is strongly associated with antibodies. b Western blot against Abeta in the empty volume (IgM) fraction and IgM showing the presence of Abeta in the IgM fraction
###end p 26
###begin p 27
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 296 297 293 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 366 367 363 364 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 379 387 373 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">diamonds</italic>
###xml 497 507 491 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid line</italic>
a Sandwich ELISA. 96-well titer plates are coated with anti-Abeta (4G8). After incubation with plasma samples, the wells are washed and incubated with an anti-IgM heavy chain antibody conjugated with HRP. Signal of bound molecules is therefore only produced by complexes of both IgM and antigen. b Calibration curve obtained by serial dilutions of the IgM fraction. c Abeta-IgM (diamonds) immune complexes in the fractions derived from gel-filtration HPLC compared to total protein concentration (solid line)
###end p 27
###begin p 28
###xml 523 524 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 530 531 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 600 601 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 603 609 597 603 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 649 650 640 641 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 724 725 712 713 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 800 801 788 789 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 609 972 603 960 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Analysis of A&#946;&#8211;IgM immune complexes. <bold>a</bold> Levels of A&#946;&#8211;IgM immune complexes in the different diagnostic groups. <bold>b</bold> The comparison of the mean values do not show any significant difference. <bold>c</bold> ROC curve analysis shows a certain difference in the distribution of the immune complexes plasma concentration between AD and HC groups, which however was not significant</p>
###xml 609 972 603 960 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Analysis of A&#946;&#8211;IgM immune complexes. <bold>a</bold> Levels of A&#946;&#8211;IgM immune complexes in the different diagnostic groups. <bold>b</bold> The comparison of the mean values do not show any significant difference. <bold>c</bold> ROC curve analysis shows a certain difference in the distribution of the immune complexes plasma concentration between AD and HC groups, which however was not significant</p></caption>
###xml 972 972 960 960 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2009_224_Fig3_HTML" id="MO3"/>
###xml 603 972 597 960 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="29">Analysis of A&#946;&#8211;IgM immune complexes. <bold>a</bold> Levels of A&#946;&#8211;IgM immune complexes in the different diagnostic groups. <bold>b</bold> The comparison of the mean values do not show any significant difference. <bold>c</bold> ROC curve analysis shows a certain difference in the distribution of the immune complexes plasma concentration between AD and HC groups, which however was not significant</p></caption><graphic position="anchor" xlink:href="702_2009_224_Fig3_HTML" id="MO3"/></fig>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 80 82 <span type="species:ncbi:9606">AD</span>
###xml 538 540 <span type="species:ncbi:9606">AD</span>
###xml 556 558 <span type="species:ncbi:9606">AD</span>
###xml 921 923 <span type="species:ncbi:9606">AD</span>
To assess the relevance of these findings, plasma samples from 75 patients with AD, MCI, and from healthy donors were analyzed for the presence of Abeta-IgM ICs. Serial dilutions of the gel filtration-purified IC fraction have been used to draw a reference calibration curve. By interpolation with the standard curve, Abeta-IgM IC concentration in the plasma samples has been expressed in arbitrary units (AU)/ml. According to ANOVA test, no significant differences among the three diagnostic groups were observed (Student t test P value AD vs. HC = 0.18, AD vs. MCI = 0.61, MCI vs. HC = 0.10) (Fig. 3).Fig. 3Analysis of Abeta-IgM immune complexes. a Levels of Abeta-IgM immune complexes in the different diagnostic groups. b The comparison of the mean values do not show any significant difference. c ROC curve analysis shows a certain difference in the distribution of the immune complexes plasma concentration between AD and HC groups, which however was not significant
###end p 28
###begin p 29
###xml 40 41 37 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 115 116 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 191 192 185 186 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 312 314 <span type="species:ncbi:9606">AD</span>
Analysis of Abeta-IgM immune complexes. a Levels of Abeta-IgM immune complexes in the different diagnostic groups. b The comparison of the mean values do not show any significant difference. c ROC curve analysis shows a certain difference in the distribution of the immune complexes plasma concentration between AD and HC groups, which however was not significant
###end p 29
###begin p 30
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 163 170 163 170 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 170 427 170 424 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Comparison of specificity, sensitivity, positive predictive value (PPV&#160;=&#160;true positive (TP)/TP&#160;+&#160;false positive), negative predictive value (NPV&#160;=&#160;true negative (TN)/TN&#160;+&#160;false negative) of A&#946;-IgM comparing AD patients with the healthy control (HC) group</p>
###xml 170 427 170 424 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Comparison of specificity, sensitivity, positive predictive value (PPV&#160;=&#160;true positive (TP)/TP&#160;+&#160;false positive), negative predictive value (NPV&#160;=&#160;true negative (TN)/TN&#160;+&#160;false negative) of A&#946;-IgM comparing AD patients with the healthy control (HC) group</p></caption>
###xml 427 436 424 433 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Biomarker</th>
###xml 436 451 433 448 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cut-off (AU/mL)</th>
###xml 451 462 448 459 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sensitivity</th>
###xml 462 473 459 470 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Specificity</th>
###xml 473 476 470 473 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PPV</th>
###xml 476 479 473 476 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NPV</th>
###xml 427 479 424 476 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Biomarker</th><th align="left">Cut-off (AU/mL)</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">PPV</th><th align="left">NPV</th></tr>
###xml 427 479 424 476 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Biomarker</th><th align="left">Cut-off (AU/mL)</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">PPV</th><th align="left">NPV</th></tr></thead>
###xml 479 488 476 482 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">A&#946;-IgM</td>
###xml 488 493 482 487 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&lt;1926</td>
###xml 493 504 487 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">80% (24/30)</td>
###xml 504 518 498 512 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">46.67% (16/30)</td>
###xml 518 521 512 515 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60%</td>
###xml 521 524 515 518 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">70%</td>
###xml 479 524 476 518 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">A&#946;-IgM</td><td align="left">&lt;1926</td><td align="left">80% (24/30)</td><td align="left">46.67% (16/30)</td><td align="left">60%</td><td align="left">70%</td></tr>
###xml 524 530 518 524 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&lt;648.5</td>
###xml 530 543 524 537 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26.67% (8/30)</td>
###xml 543 553 537 547 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">80% (6/30)</td>
###xml 553 556 547 550 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">57%</td>
###xml 556 559 550 553 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">52%</td>
###xml 524 559 518 553 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&lt;648.5</td><td align="left">26.67% (8/30)</td><td align="left">80% (6/30)</td><td align="left">57%</td><td align="left">52%</td></tr>
###xml 479 559 476 553 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="2">A&#946;-IgM</td><td align="left">&lt;1926</td><td align="left">80% (24/30)</td><td align="left">46.67% (16/30)</td><td align="left">60%</td><td align="left">70%</td></tr><tr><td align="left">&lt;648.5</td><td align="left">26.67% (8/30)</td><td align="left">80% (6/30)</td><td align="left">57%</td><td align="left">52%</td></tr></tbody>
###xml 427 559 424 553 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Biomarker</th><th align="left">Cut-off (AU/mL)</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">PPV</th><th align="left">NPV</th></tr></thead><tbody><tr><td align="left" rowspan="2">A&#946;-IgM</td><td align="left">&lt;1926</td><td align="left">80% (24/30)</td><td align="left">46.67% (16/30)</td><td align="left">60%</td><td align="left">70%</td></tr><tr><td align="left">&lt;648.5</td><td align="left">26.67% (8/30)</td><td align="left">80% (6/30)</td><td align="left">57%</td><td align="left">52%</td></tr></tbody></table>
###xml 163 559 163 553 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="31">Comparison of specificity, sensitivity, positive predictive value (PPV&#160;=&#160;true positive (TP)/TP&#160;+&#160;false positive), negative predictive value (NPV&#160;=&#160;true negative (TN)/TN&#160;+&#160;false negative) of A&#946;-IgM comparing AD patients with the healthy control (HC) group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Biomarker</th><th align="left">Cut-off (AU/mL)</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">PPV</th><th align="left">NPV</th></tr></thead><tbody><tr><td align="left" rowspan="2">A&#946;-IgM</td><td align="left">&lt;1926</td><td align="left">80% (24/30)</td><td align="left">46.67% (16/30)</td><td align="left">60%</td><td align="left">70%</td></tr><tr><td align="left">&lt;648.5</td><td align="left">26.67% (8/30)</td><td align="left">80% (6/30)</td><td align="left">57%</td><td align="left">52%</td></tr></tbody></table></table-wrap>
###xml 237 240 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
###xml 380 382 <span type="species:ncbi:9606">AD</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
ROC curve analysis showed that specificity was only 46.67% when sensitivity was set at 80%, and by setting specificity above 80%, sensitivity was 26.67% (Table 2).Table 2Comparison of specificity, sensitivity, positive predictive value (PPV = true positive (TP)/TP + false positive), negative predictive value (NPV = true negative (TN)/TN + false negative) of Abeta-IgM comparing AD patients with the healthy control (HC) groupBiomarkerCut-off (AU/mL)SensitivitySpecificityPPVNPVAbeta-IgM<192680% (24/30)46.67% (16/30)60%70%<648.526.67% (8/30)80% (6/30)57%52%
###end p 30
###begin p 31
###xml 67 70 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
###xml 210 212 <span type="species:ncbi:9606">AD</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
Comparison of specificity, sensitivity, positive predictive value (PPV = true positive (TP)/TP + false positive), negative predictive value (NPV = true negative (TN)/TN + false negative) of Abeta-IgM comparing AD patients with the healthy control (HC) group
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 428 433 425 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4"> 2005</xref>
###xml 435 439 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2007</xref>
###xml 441 445 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2008</xref>
###xml 463 467 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2005</xref>
###xml 691 695 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2001</xref>
###xml 712 716 703 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">1998</xref>
###xml 731 735 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1998</xref>
###xml 752 756 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2004</xref>
###xml 773 777 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2000</xref>
###xml 908 912 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2007</xref>
###xml 927 931 915 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2000</xref>
###xml 933 937 921 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2001</xref>
###xml 961 965 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2000</xref>
###xml 1120 1124 1105 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">2008</xref>
###xml 1334 1338 1313 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2006</xref>
###xml 1354 1358 1333 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2008</xref>
###xml 1460 1464 1436 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">1997</xref>
###xml 1483 1487 1459 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">1999</xref>
###xml 1537 1541 1513 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2003</xref>
###xml 1558 1562 1534 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">1996</xref>
###xml 1765 1769 1738 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2005</xref>
###xml 1833 1837 1800 1804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">2006</xref>
###xml 1871 1875 1838 1842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2007</xref>
###xml 2156 2160 2114 2118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2001</xref>
###xml 2177 2181 2135 2139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2002</xref>
###xml 2222 2226 2180 2184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2003</xref>
###xml 2339 2343 2294 2298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2001</xref>
###xml 84 86 <span type="species:ncbi:9606">AD</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 266 268 <span type="species:ncbi:9606">AD</span>
###xml 622 624 <span type="species:ncbi:9606">AD</span>
###xml 1057 1059 <span type="species:ncbi:9606">AD</span>
###xml 1060 1068 <span type="species:ncbi:9606">patients</span>
###xml 1252 1254 <span type="species:ncbi:9606">AD</span>
###xml 1305 1307 <span type="species:ncbi:9606">AD</span>
###xml 1433 1435 <span type="species:ncbi:9606">AD</span>
###xml 1436 1444 <span type="species:ncbi:9606">patients</span>
###xml 1672 1674 <span type="species:ncbi:9606">AD</span>
###xml 1911 1913 <span type="species:ncbi:9606">AD</span>
###xml 2101 2103 <span type="species:ncbi:9606">AD</span>
###xml 2104 2112 <span type="species:ncbi:9606">patients</span>
###xml 2197 2199 <span type="species:ncbi:9606">AD</span>
###xml 2200 2208 <span type="species:ncbi:9606">patients</span>
The aim of the present study was to analyze the serological profile of samples from AD and MCI patients, and healthy controls, regarding the levels of Abeta-IgM complexes, and to evaluate a possible correlation between the immunological profiles of individuals with AD. Immune complexes, in fact, have recently been proven to correlate better than unbound biomarkers with pathology in different cancer entities (Beneduce et al.  2005, 2007, 2008; Castaldi et al. 2005), which are characterized by an over- or mis-production of an endogenous protein. At present, only CSF Abeta42 levels is a well established Abeta-related AD biomarker with high sensitivity and specificity (Andreasen et al. 2001; Galasko et al. 1998; Kanai et al. 1998; Lewczuk et al. 2004; Tapiola et al. 2000). Unfortunately, there seems to be no correlation between CSF and blood Abeta level, as shown by several groups (Matsumoto et al. 2007; Mehta et al. 2000, 2001; Vanderstichele et al. 2000). A longitudinal study showed that CSF Abeta42 decreases within 12 months significantly in AD patients, while Tau and Phospho-Tau did not (Kessler et al. 2008). Although much better for clinical practice, blood-based Abeta levels are controversially discussed as a useful biomarker for AD. Studies have shown a decreased level of Abeta in AD subjects (Pesaresi et al. 2006; Xu and Gaskin 2008), while others showed an increase of Abeta concentration in the plasma of AD patients (Kosaka et al. 1997; Matsubara et al. 1999), or no statistical differences (Fukumoto et al. 2003; Tamaoka et al. 1996). The same inconsistency emerged from a series of prospective studies, in which a higher risk for developing AD has been associated both with higher baseline plasma Abeta42 concentration (Pomara et al. 2005) or higher Abeta40 with no effect on Abeta42 (van Oijen et al. 2006). Finally, Graff-Radford et al. (2007) linked a high risk for developing AD to a lower Abeta42/40 ratio. Plasma anti-Abeta autoantibody concentration has also been investigated by several groups. Titers of anti-Abeta42 autoantibodies were reported to be lower in AD patients compared to healthy individuals (Du et al. 2001; Weksler et al. 2002), or higher in AD patients (Nath et al. 2003). One study reported no correlation between autoantibodies titers and plasma Abeta40 or 42 levels (Hyman et al. 2001).
###end p 33
###begin p 34
###xml 542 546 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2007</xref>
###xml 617 621 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2005</xref>
###xml 719 724 716 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3"> 2004</xref>
###xml 726 730 723 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 836 840 833 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2008</xref>
###xml 853 857 850 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">2007</xref>
###xml 99 101 <span type="species:ncbi:9606">AD</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
The initial goal of this study was to characterize the occurrence of ICs of Abeta in the plasma of AD and MCI patients and HC, as seen with many cancer biomarkers. It is well known that IgM complexes are in equilibrium in blood with the unbound respective antigen and are used as reliable blood biomarkers for diagnosis of different cancer entities. It would make sense that the same equilibrium holds true for any IgM complex in blood. Already established immune complexes as biomarkers include: PSA-IgM for prostate cancer (Beneduce et al. 2007), carcinoembryonic antigen-IgM for colorectal cancer (Castaldi et al. 2005) alpha fetoprotein-IgM and squamous cell carcinoma antigen-IgM for liver cancer (Beneduce et al.  2004, 2005). Moreover, IgM immune complexes have also been shown to be uncorrelated with basal IgM levels (Beneduce 2008). Nydegger (2007) discussed in a review article biochemical properties of immune complexes in general, their formation and their equilibrium state, stating that immune complex interaction is extremely high compared to other biochemical interactions.
###end p 34
###begin p 35
###xml 507 511 495 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2007</xref>
###xml 915 919 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">1998</xref>
###xml 23 25 <span type="species:ncbi:9606">AD</span>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 369 371 <span type="species:ncbi:9606">AD</span>
###xml 583 585 <span type="species:ncbi:9606">AD</span>
###xml 771 773 <span type="species:ncbi:9606">AD</span>
###xml 774 782 <span type="species:ncbi:9606">patients</span>
###xml 925 927 <span type="species:ncbi:9606">AD</span>
Plasma samples from 30 AD patients, 15 MCI patients, and 30 age- and sex-matched HC have been analyzed to determine the levels of circulating Abeta-IgM ICs. After gel-filtration and size fractionation, Abeta was primarily found to be associated with the IgM and the IgG fractions using an ELISA. This is the first characterization of circulating Abeta-IgM complexes in AD. The Abeta-IgM assay did not show any significant difference among the three groups, in contrast with previous findings (Gruden et al. 2007), proving that although there is great interest around autoimmunity in AD, IC levels cannot be used as a diagnostic marker. It should be noted, however, that variability of IC level was high within the groups. This high variance leading to an overlap between AD patients and healthy controls might be partly due to biological variability. Consensus criteria for a suitable biomarker (Trojanowski et al. 1998) for AD were however not met.
###end p 35
###begin p 36
###xml 808 812 805 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2003</xref>
###xml 1324 1328 1309 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2002</xref>
###xml 316 318 <span type="species:ncbi:9606">AD</span>
###xml 459 461 <span type="species:ncbi:9606">AD</span>
###xml 649 651 <span type="species:ncbi:9606">AD</span>
###xml 936 944 <span type="species:ncbi:9606">patients</span>
###xml 1036 1044 <span type="species:ncbi:9606">patients</span>
###xml 1249 1257 <span type="species:ncbi:9606">patients</span>
###xml 1263 1265 <span type="species:ncbi:9606">AD</span>
On the other hand, the presence of circulating ICs against neuronal antigens supports the notion that autoimmune-mediated processes may be involved in neurodegenerative disorders. Further investigations are needed to elucidate the pathophysiological role of these complexes and the significance of autoantibodies in AD in general. Whether their role is neuroprotective or neurotoxic is still unknown. They may be seen both as a possible protective factor for AD, or as a risk factor in case of an unbalanced level. In any case, autoimmunity-driven homeostasis is a natural process and its understanding may be useful in both diagnosing and treating AD; there are evidences for a therapeutic use of anti-Abeta antibodies as it is being shown by current experimental immunotherapeutic approaches. Hock et al. (2003) showed that active immunization against aggregated Abeta42 led to a slower cognitive decline in a dose-dependent fashion; patients generating a higher titer of anti-Abeta antibodies performed better in cognitive test than patients who did not respond to the immunization protocol. The increase in antibody titer did not correspond to a decrease in Abeta blood levels. In contrast, significant changes were observed in serum and CSF of patients with AD after treatment with intravenous Abeta IgGs (Dodel et al. 2002).
###end p 36
###begin p 37
###xml 485 489 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2007</xref>
###xml 577 581 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">1997</xref>
###xml 656 660 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2004</xref>
###xml 907 911 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2001</xref>
###xml 1017 1021 996 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2005</xref>
###xml 1035 1039 1014 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2003</xref>
###xml 1055 1059 1034 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">2002</xref>
###xml 115 117 <span type="species:ncbi:9606">AD</span>
###xml 667 682 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1194 1202 <span type="species:ncbi:9606">patients</span>
###xml 1213 1215 <span type="species:ncbi:9606">AD</span>
###xml 1216 1224 <span type="species:ncbi:9606">patients</span>
The levels of Abeta autoantibodies of the IgG class for monitoring the effect of passive or active immunization in AD have already been evaluated by recent studies. It is speculative to discuss a possible role of Abeta-IgM levels as a predictive indicator of immunotherapy efficacy. A possible hypothesis includes that they serve as a "buffering system" to keep free potential toxic endogenous peptides and proteins under homeostatic control and lead to their clearance (Gruden et al. 2007). Previous studies have shown the presence of anti-Abeta autoantibodies (Xu and Gaskin 1997) and circulating IC of Abeta and IgGs of different classes (Gruden et al. 2004). APP transgenic mice injected intravenously with monoclonal anti-Abeta antibody showed a rapid and massive increase of CNS-derived Abeta in the plasma suggesting that antibodies may participate in Abeta clearance from the brain (DeMattos et al. 2001). However, whether this immune activity is defensive or toxic is still a matter of debate (Geylis et al. 2005; Nath et al. 2003; Woulfe et al. 2002). It will be interesting to evaluate in future studies possible relationships of Abeta-IC levels with the clinical development of MCI patients, and with AD patients' response to immune therapies.
###end p 37
###begin p 38
The excellent technical help of Petra Tucholla is gratefully acknowledged. Financial support was provided by the European Commission, Marie Curie Early Stage Training, MEST-CT-2005-020013 (NEURAD), International Alzheimer Ph.D. Graduate School.
###end p 38
###begin p 39
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
###end article-title 41
###begin article-title 42
Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes
###end article-title 42
###begin article-title 43
Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma
###end article-title 43
###begin article-title 44
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients
###end article-title 44
###begin article-title 45
Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma
###end article-title 45
###begin article-title 46
###xml 67 72 <span type="species:ncbi:9606">human</span>
Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma
###end article-title 46
###begin article-title 47
Cerebrospinal fluid protein biomarkers for Alzheimer's disease
###end article-title 47
###begin article-title 48
Detection of circulating CEA-IgM complexes in early stage colorectal cancer
###end article-title 48
###begin article-title 49
Detection of circulating CEA-IgM complexes in early stage colorectal cancer Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma
###end article-title 49
###begin article-title 50
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease
###end article-title 50
###begin article-title 51
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease
###end article-title 51
###begin article-title 52
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease
###end article-title 52
###begin article-title 53
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels
###end article-title 53
###begin article-title 54
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
###end article-title 54
###begin article-title 55
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monoclonal antibodies against amyloid-beta from healthy adults
###end article-title 55
###begin article-title 56
The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease
###end article-title 56
###begin article-title 57
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease
###end article-title 57
###begin article-title 58
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease
###end article-title 58
###begin article-title 59
Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta(25-35) oligomers, S100b and neurotransmitters
###end article-title 59
###begin article-title 60
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics
###end article-title 60
###begin article-title 61
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease
###end article-title 61
###begin article-title 62
Autoantibodies to amyloid-beta and Alzheimer's disease
###end article-title 62
###begin article-title 63
Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression
###end article-title 63
###begin article-title 64
Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan
###end article-title 64
###begin article-title 65
Plasma biomarkers of Alzheimer's disease
###end article-title 65
###begin article-title 66
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial
###end article-title 66
###begin article-title 67
The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43)
###end article-title 67
###begin article-title 68
Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma
###end article-title 68
###begin article-title 69
Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma
###end article-title 69
###begin article-title 70
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau
###end article-title 70
###begin article-title 71
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome
###end article-title 71
###begin article-title 72
Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease
###end article-title 72
###begin article-title 73
Inflammation, autotoxicity and Alzheimer disease
###end article-title 73
###begin article-title 74
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
###end article-title 74
###begin article-title 75
Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease
###end article-title 75
###begin article-title 76
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease
###end article-title 76
###begin article-title 77
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease
###end article-title 77
###begin article-title 78
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development
###end article-title 78
###begin article-title 79
Immune complex pathophysiology
###end article-title 79
###begin article-title 80
Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment
###end article-title 80
###begin article-title 81
Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report
###end article-title 81
###begin article-title 82
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease
###end article-title 82
###begin article-title 83
Neuroautoimmunity: pathogenic implications for Alzheimer's disease
###end article-title 83
###begin article-title 84
###xml 78 81 <span type="species:ncbi:9606">men</span>
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study
###end article-title 84
###begin article-title 85
An increased percentage of long amyloid beta protein is secreated by familial amyloid beta protein precursor (betaAPP717) mutants
###end article-title 85
###begin article-title 86
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease
###end article-title 86
###begin article-title 87
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease
###end article-title 87
###begin article-title 88
Intrathecal inflammation precedes development of Alzheimer's disease
###end article-title 88
###begin article-title 89
###xml 71 79 <span type="species:ncbi:9606">patients</span>
APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease
###end article-title 89
###begin article-title 90
A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research
###end article-title 90
###begin article-title 91
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study
###end article-title 91
###begin article-title 92
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma
###end article-title 92
###begin article-title 93
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals
###end article-title 93
###begin article-title 94
Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
###end article-title 94
###begin article-title 95
Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD
###end article-title 95
###begin article-title 96
###xml 68 86 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease
###end article-title 96
###begin article-title 97
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls
###end article-title 97
###begin article-title 98
Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects
###end article-title 98

